Latest studies
- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS) KEYNOTE-091
This study looks at a drug called Keytruda after surgery for a type of lung cancer. It aims to see if Keytruda can stop the cancer from coming back for longer than a dummy treatment in patients with non-small cell lung cancer, especially those with certain cancer markers.
Stage IB (T ≥ 4 cm), II and IIIA NSCLCDenmark - AuthorisedTherapeutic confirmatory (Phase III)
High Dose Steroids in Children with Stroke and Unilateral Focal Arteriopathy: A Multicentre Randomized Controlled Trial
This study looks at using strong steroid medicines to treat a type of stroke in children called focal cerebral arteriopathy (FCA). Researchers want to see if these medicines can reduce the inflammation in blood vessels and improve children's recovery.
Focal cerebral arteriopathy and childhood strokeFocal cerebral arteriopathy (FCA) is an inflammatory vessel wall diseaseprovoked by infection.Denmark - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of NMD670 over 21 days in Ambulatory Adult Patients with Charcot-Marie-Tooth Disease Type 1 and Type 2
This study is testing a new medicine, NMD670, for people with Charcot-Marie-Tooth disease types 1 and 2. It compares the medicine to a dummy pill to see if it helps people walk further and if it's safe over 21 days. Participants will be adults who can walk.
Charcot-Marie-Tooth Disease Type 1 and Type 2Denmark - Recruiting
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
This study looks at how well Medtronic heart devices, like pacemakers and defibrillators, perform over a long time. It helps ensure these devices are reliable and safe for people with heart conditions such as irregular heartbeats or heart failure.
ArrhythmiaBradycardiaHeart FailureSinus TachycardiaDenmark - Ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
Phase 1 Trial of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of RP-1664 in Participants with Advanced Solid Tumors
This early-stage study is testing a new unproven medicine called RP-1664 for people with advanced solid tumours that have spread. We want to check its safety, how it moves through the body, and if it shows any early signs of helping to shrink tumours. It's the first time this drug is being given to humans.
Advanced Solid TumorsDenmark - Active not recruitingPHASE3
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
This study looks at a new combination of medicines, enzalutamide and leuprolide, for men with prostate cancer that hasn't spread but is considered high-risk. The goal is to see how safe and effective this combination is in slowing down the cancer.
Hormone Sensitive Prostate CancerProstate CancerCancer of the ProstateDenmark - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Multicenter, Open-label Study to Evaluate the Efficacy, Pharmacokinetics, Safety, and Immunogenicity of Subcutaneously Administered Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis (PSUMMIT-Jr)
This study looks at two medicines, Stelara and Guselkumab, for young people with a type of arthritis called juvenile psoriatic arthritis. It checks how well they work, how safe they are, and how the body handles them.
Juvenile psoriatic arthritisDenmark - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to investigate the efficacy and safety of secukinumab 300 mg and 150 mg administered subcutaneously versus placebo, in combination with a glucocorticoid taper regimen, in patients with giant cell arteritis (GCA) (GCAptAIN)
This study is testing a new medicine, secukinumab, for giant cell arteritis (GCA). It compares different doses of secukinumab with a dummy medicine (placebo), alongside a common steroid treatment. The aim is to see if secukinumab can help people with GCA stay well for longer.
Giant cell arteritis (GCA)Denmark - Recruiting
Exploring the hidden burden of living with Glanzmann thrombasthenia
This study wants to hear from people living with Glanzmann thrombasthenia (GT) and their caregivers. We want to understand the daily challenges and feelings of those affected. Your stories can help improve support and understanding for everyone with GT.
Glanzmann thrombastheniaDenmark - Ongoing, recruitingTherapeutic exploratory (Phase II)
Interventional, randomized, double-blind, parallel-group, placebo-controlled, dose-finding trial of Lu AG09222 for the prevention of migraine in participants with episodic and chronic migraine. Lundbeck trial no: 20297A
This study is testing a new medicine, Lu AG09222, to see if it can help prevent migraines. It's for people who get migraines often, including those with episodic (comes and goes) and chronic (very frequent) migraine. Researchers want to find the best dose to reduce migraine days.
MigraineDenmark - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib in Subjects with Giant Cell Arteritis
This study is testing a new medicine, upadacitinib, for giant cell arteritis (GCA). Researchers want to see if it can help people stay well and reduce the need for steroid medicines, comparing it to a dummy medicine.
Giant Cell ArteritisDenmark - Active not recruitingPHASE1, PHASE2
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
This study is looking into a new treatment, CC-99282, for non-Hodgkin lymphoma that has returned or not responded to other treatments. Researchers want to see how safe it is and how well it works, both by itself and with other lymphoma medicines.
Lymphoma, Non-HodgkinDenmark - Active not recruitingPHASE3
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy
This study looks at whether fezolinetant can reduce hot flashes in women with breast cancer who are having hormone therapy. These hot flashes are a common side effect, and current treatments like HRT aren't suitable. We want to see if fezolinetant helps more than a dummy pill.
Hot FlashesDenmark - RecruitingPHASE4
A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies
This study looks into why some breast cancers stop responding to treatment. We will examine tissue and blood samples from patients with specific types of breast cancer to understand how the cancer becomes resistant and find new ways to help them.
Breast CancerDenmark - RecruitingPHASE3
Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
This study looks at a new way to treat a specific type of leukaemia (AML) with a gene change called IDH1. It adds a drug called venetoclax to standard treatment (ivosidenib and azacitidine) to see if it works better. It's for patients who can't have strong chemotherapy.
Acute Myeloid LeukemiaDenmark - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
The headache-inducing effects of sildenafil in men and women with episodic migraine without aura.
This study looks at how a drug called sildenafil (typically for erectile dysfunction, but also used for pulmonary hypertension) affects migraine headaches in men and women who get migraines without aura. It compares sildenafil to a dummy pill and other migraine treatments.
Migraine without auraDenmark - Active not recruitingNA
Evaluation of Safety and Performance of the Omega™ LAA (Left Atrial Appendage) Occluder and Omega™ Delivery System in Patients With Non-Valvular Atrial Fibrillation and High Bleeding Risk
This study looks at a new device, the Omega LAA Occluder, designed to prevent strokes in people with a type of irregular heartbeat called non-valvular atrial fibrillation, especially if they have a high risk of bleeding. It checks how safe and effective the device is.
Non-Valvular Atrial FibrillationDenmark - Active not recruitingPHASE3
A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
This study is testing new drug combinations, pozelimab and cemdisiran, for adults with a muscle-weakening condition called generalised myasthenia gravis (gMG). It looks at how safe these drugs are and how well they help improve muscle function.
Generalized Myasthenia GravisDenmark - RecruitingPHASE3
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
This study is looking into a new medication called Afimkibart for people aged 16-80 with ulcerative colitis that is moderately to severely active. It aims to see how well it works and if it's safe compared to a dummy drug. We hope it could be a new treatment option.
Moderately to Severely Active Ulcerative ColitisDenmark - Completed
An international cohort study of wound closure and surgical site infection prevention strategies in abdominal surgery
This study looks at how different ways of closing wounds and preventing infections after tummy surgery affect how well people recover. It aims to improve future surgical care worldwide by gathering information from adults undergoing these operations.
Adult patients (age 18 years and above) undergoing general or colorectal surgical procedures using any type of abdominal incision measuring at least 5 cm (including extraction sites)Denmark - RecruitingPhase III
A long-term extension (LTE) study of guselkumab in pediatric participants
This study looks at the long-term safety of a medicine called guselkumab for children and young people aged 2-17 with Crohn's disease, ulcerative colitis, or a type of arthritis called juvenile psoriatic arthritis. It's for those who have already benefited from guselkumab in a previous study.
Moderately to severely active ulcerative colitis (UC), moderately to severely active Crohn's disease (CD), Juvenile psoriatic arthritis (jPsA)Denmark - RecruitingPHASE3
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
This study looks at a new drug, sevabertinib, for advanced lung cancer with a specific genetic change (HER2 mutation). It compares sevabertinib to standard treatments to see if it works better and is safe.
Advanced Non-small Cell Lung Cancer, HER2 MutationDenmark - Ongoing, recruitingTherapeutic confirmatory (Phase III)
ATLAS-OLE: An Open-label, Long-term Safety and Efficacy Study of Fitusiran in Patients with Hemophilia A or B, with or without Inhibitory Antibodies to Factor VIII or IX
This study is testing a new medicine, fitusiran, for people with haemophilia A or B. It wants to see how safe and effective it is over a long time, especially in stopping bleeding. Doctors are looking at side effects and how it improves daily life.
Hemophilia A or Hemophilia BDenmark - AuthorisedTherapeutic confirmatory (Phase III)
A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
This study looks at a new drug, INCA33890, alongside standard treatments for advanced bowel cancer that has spread. It aims to see if adding INCA33890 helps people live longer and keeps the cancer from growing for a longer time.
Metastatic Microsatellite Stable Colorectal CancerDenmark - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough
This study looks at a new medicine called BI 1839100. It's for people with lung conditions like Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF) who have a troublesome cough. We want to see if the medicine can reduce coughing and if it's safe to use.
Progressive pulmonary fibrosis (PPF), Idiopathic pulmonary fibrosis (IPF)Denmark - Ongoing, recruitingPhase II and Phase III (Integrated)
Multicenter, Prospective, Open-label, Randomized, Crossover Study to Evaluate Pharmacokinetics (PK), Safety, and Tolerability of TAK-881 in Primary Immunodeficiency Diseases (PIDD)
This study is looking at a new treatment called TAK-881 for people with primary immunodeficiency diseases (PIDD). Researchers want to understand how the body uses TAK-881, if it's safe, and if it helps prevent infections. It compares TAK-881 to an existing treatment, HyQvia.
Primary Immunodeficiency DiseasesDenmark - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2b, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study of Batoclimab Treatment in Adult Participants with Active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
This study is testing a new medicine, Batoclimab, for adults with a condition called Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Researchers want to see if this medicine can stop CIDP symptoms from getting worse, compared to a dummy medicine. It's an important step to find better treatments.
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Denmark - RecruitingPHASE3
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
This study is looking at new drug combinations for people recently diagnosed with a type of blood cancer called multiple myeloma. It compares two new treatments, Teclistamab or Talquetamab, each given with standard drugs, against the usual standard treatment, to see which works best.
Multiple MyelomaDenmark - Active not recruitingPHASE1
ATA-100 (Formerly GNT0006) Gene Therapy Trial in Patients With LGMDR9
This study is testing a new gene therapy, called ATA-100, for people with a rare muscle condition called LGMDR9. We want to see if it's safe and how it affects the body. Up to six adults will take part, and we'll watch them closely for five years.
LGMDR9Denmark - Ongoing, recruitingTherapeutic exploratory (Phase II)
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety and tolerability of different doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF).
This study is testing a new medicine, BI 1819479, for idiopathic pulmonary fibrosis (IPF). We want to see if it can slow down the lung scarring and if it's safe. Some people will get the medicine, others a dummy pill. We'll check how your breathing changes over about a year.
idiopathic pulmonary fibrosisDenmark - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension
This study looks at a new medicine called Mavorixafor for people with WHIM syndrome. It compares the medicine to a dummy pill to see if it helps improve the body's infection-fighting cells and reduce warts and infections. It also checks how safe the medicine is.
WHIM SyndromeDenmark - Active not recruitingPHASE3
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
This study is looking at a new medicine called Xaluritamig for men with advanced prostate cancer that has stopped responding to standard hormone therapy. It compares Xaluritamig to existing treatments like Cabazitaxel or other hormone therapies, to see which is more effective at helping men live longer.
Metastatic Castration-resistant Prostate CancerDenmark - Active not recruitingPHASE3
A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
This study compares new drug combinations (dostarlimab and niraparib) with standard care for women newly diagnosed with advanced ovarian cancer. It aims to see if these new treatments can stop the cancer from growing for longer.
Ovarian NeoplasmsOvarian, Fallopian Tube and Primary Peritoneal CarcinomaDenmark - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Ranibizumab, Compared with Ranibizumab Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)
This study looks at a new drug, OPT-302, combined with an existing treatment (Lucentis) for 'wet' age-related macular degeneration (AMD). It aims to see if the combination works better than Lucentis alone to improve or maintain vision over one year.
Neovascular age-related macular degeneration (wet AMD)Denmark - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Hydralazine-ISDN in Patients With Chronic Heart Failure - Hydralazine Heart Failure Trial (H-HeFT) Metformin in Patients with Chronic Heart Failure and Diabetes or Insulin Resistance - Metformin Heart Failure Trial (Met-HeFT) A randomized, 2 x 2 factorial designed, double-blind, placebo controlled study (DANHEART).
This study looks at two different treatments, BiDil and Metformin, for people with long-term heart failure. Researchers want to see if these treatments can reduce serious events like hospital stays, heart transplants, or heart attacks, and improve overall health.
Heart failureDenmark - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A 104-WEEK, MULTICENTER, SINGLE-ARM, LONG-TERM, PHASE 3 EXTENSION TRIAL INVESTIGATING THE SAFETY AND EFFICACY OF GLEPAGLUTIDE IN ADULT PATIENTS WITH SHORT BOWEL SYNDROME (SBS) COMPLETING THE EASE SBS 2 TRIAL
This study looks at a new medicine called glepaglutide for adults with short bowel syndrome. It checks how safe and effective it is over a long time, especially what side effects people might have and if it helps reduce their need for IV feeding.
Short bowel syndromeDenmark - Ongoing, recruitingTherapeutic use (Phase IV)
Open label, Multicenter, Prospective Study to Characterize the Pharmacokinetics and Pharmacodynamics of Cufence (Trientine Dihydrochloride) and to Investigate the Efficacy and Safety in Wilson’s Disease Patients
This study looks at a medicine called Cufence for people with Wilson's Disease. It checks how the body handles the medicine and how well it works. It also makes sure it's safe to use.
Wilson’s DiseaseDenmark - AuthorisedHuman Pharmacology (Phase I)- Other
Adding oxygen to enhance antibiotic treatment of chronic lung infection
Researchers are looking into whether adding oxygen can help antibiotics work better for long-term lung infections, especially in people with conditions like cystic fibrosis or primary ciliary dyskinesia. This early study aims to see if this treatment is safe and how it affects the body.
Primary ciliary dyskinesia, Chronic pulmonary Pseudomonas aeruginosa infection, Cystic fibrosisDenmark - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
This study is testing a new medicine, BI 1015550, for people with progressive fibrosing interstitial lung diseases (PF-ILDs). Researchers want to see if it helps improve lung function and is safe to use over about a year.
Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)Denmark - RecruitingPHASE3
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
This study looks at a new way to treat a common eye condition called wet Age-related Macular Degeneration (AMD). It tests a small, refillable implant that delivers medicine directly to the eye, hoping to reduce how often people need eye injections.
Neovascular Age-related Macular DegenerationDenmark - RecruitingPHASE3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
This study looks at the long-term safety and effectiveness of a cancer drug called pembrolizumab (and related treatments) for people with advanced cancers. It's for patients who are already receiving these treatments in other studies and want to continue.
Solid TumorsHematologic MalignanciesDenmark - Active not recruitingPHASE3
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
This study looks at new treatments for HER2-positive breast cancer that has spread. It compares an experimental drug, trastuzumab deruxtecan (T-DXd), alone or with another drug, pertuzumab, to standard care, to see if they work better and are safe.
Breast Cancer; HER2-positive; MetastaticDenmark - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients
This study is looking at a new medicine, sotatercept, for people recently diagnosed with a serious lung condition called Pulmonary Arterial Hypertension (PAH). It compares sotatercept to a dummy medicine to see if it improves well-being and reduces serious health events when added to standard treatments.
Therapeutic confirmatory (phase III)Denmark - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients with Primary Focal Segmental Glomerulosclerosis (FSGS)
This study is testing a new medication called Sparsentan for people with a kidney condition called FSGS. It compares Sparsentan to an existing treatment (Irbesartan) to see how well it protects the kidneys and if it's safe over about two years.
Focal segmental glomerulosclerosis (FSGS)Denmark - Active not recruitingPHASE3
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
This study compares a new cell therapy (Cilta-cel) with standard treatments for multiple myeloma, a type of blood cancer. It's for people whose cancer has returned or isn't responding to their current medicine, especially lenalidomide, to see if the new treatment works better.
Multiple MyelomaDenmark - Ongoing, recruitingTherapeutic exploratory (Phase II)
ApproaCH: A Phase 2b, Multicenter, Double-Blind, Randomized, Placebo-controlled Trial evaluating Efficacy and Safety of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 52 Weeks in Children with Achondroplasia followed by an Open Label Extension period
This study, called ApproaCH, is testing a new medicine called TransCon CNP for children and teenagers with achondroplasia. It wants to see if the medicine helps them grow taller over a year, compared to a dummy medicine. After this, all children will get the new medicine.
Achondroplasia in Children and AdolescentsDenmark - RecruitingPHASE1
A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis
This study is testing a new oral medication, SYX-5219, for moderate to severe eczema (atopic dermatitis). It aims to check the drug's safety, how well it's tolerated, and how it moves through the body in both healthy people and those with eczema.
Moderate to Severe Atopic DermatitisDenmark - Active not recruitingNA
REDUCE LAP-HF TRIAL II
This study looks at a new tiny device, the IASD System II, for people with heart failure. It aims to see if this implant can improve symptoms and quality of life by helping the heart manage pressure better. Half the people get the implant, and half get a check-up without it.
Heart FailureDenmark - Recruiting
Sustained Effort Network for Treatment of Status Epilepticus/European Academy of Neurology Registry on Refractory Status Epilepticus (SENSE-II/AROUSE)
This study, SENSE-II/AROUSE, is collecting information from adult patients across Europe who are being treated for a severe and prolonged seizure called Status Epilepticus. Researchers want to understand more about these seizures, how they are treated, and what factors might predict how a patient will recover.
Status EpilepticusDenmark - AuthorisedTherapeutic confirmatory (Phase III)
A randomized double-blind placebo-controlled study with ASA treatment in colorectal cancer patients with mutations in the PI3K signaling pathway
This study looks at whether a daily aspirin-like tablet helps people with certain types of bowel cancer (colon or rectal cancer) that have specific gene changes. It compares the tablet to a dummy pill to see if it stops the cancer from coming back.
Colon and rectal cancer tumor stage II-III, tumor with somatic alterationsin PIK3CA, PIK3R1 or PTENDenmark